On November 2, 2026 Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, reported that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: JP Morgan Biotech Call Series
Location: Boston, MA
Date & Time: November 6, 2026 at 2:00 pm EST
Format: Presentation

Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Location: Boston, MA
Date & Time: November 10, 2026 at 8:00 pm EST
Format: Fireside Chat

In addition, Chief Medical Officer, Roy Baynes, M.D., Ph.D., will participate in the Morgan Stanley Biotech Webcast in November:

Event: Post-ESMO: New Data & the Evolving Synthetic Lethality Landscape
Location: New York City, NY
Date & Time: November 3, 2026 at 10:30 am EST
Format: Call

Live audio/video webcasts of these presentations will be accessible through Eikon’s investor relations website at investors.eikontx.com, with an archived edition of the session available later that day and accessible for approximately 30 days after the live event.

(Press release, Eikon Therapeutics, NOV 2, 2026, View Source [SID1234674069])